Effect of pomegranate juice on paraoxonase enzyme activity in patients with type 2 diabetes

被引：45
作者：
Parsaeyan N. [1 ,4 ]
Mozaffari-Khosravi H. [2 ]
Mozayan M.R. [3 ]
机构：
[1] Department of Biochemistry, Shahid Sadoughi, University of Medical Sciences, Yazd
[2] Department of Nutrition, Shahid Sadoughi University of Medical Sciences, Yazd
[3] Department of English Language, Shahid Sadoughi University of Medical Sciences, Yazd
[4] Department of biochemistry, School of medicine, Shahid Sadoughi University of Medical Sciences, Yazd
来源：
Journal of Diabetes & Metabolic Disorders | / 11卷 / 1期
关键词：
Diabetes mellitus; Pomegranate juice; PON1; activity;
D O I：
10.1186/2251-6581-11-11
中图分类号：
学科分类号：
摘要：
Objective(s): Paraoxonase-1 (PON1), an HDL-associated enzyme, prevents lipoprotein oxidation. PON1 enzymatic activity has been shown to decrease in patients with diabetes. Paraoxonase activity. HDL capacity to bind with PON1 is possible under specific experimental conditions, such as oxidation, addition of polyphenols, or in diabetic patients with polyphenols doses. The aim of this study was the effect of pomegranate juice (PJ) on paraoxonase and arylesterase activity of PON1.Materials and methods: Fifty patients with type 2 diabetes mellitus consumed 200 ml of PJ daily for a period of 6 weeks. Blood was collected from the patients before and after PJ consumption after 12 h of fasting. Blood sugar, total cholesterol, triglyceride, LDL- C and HDL-C were measured by colorimetric kit method. The malondialdehyde concentration (μmol/L) was determined by thiobarbituric acid (TBA) assay. Paraoxonase and arylesterase activity of PON1 enzyme were measured using paraoxone and phenylacetate as the substrates.Results: The concentration of fasting blood sugar, total cholesterol, LDL-C and malondialdehyde significantly (p < 0.001) decreased after the intervention. Paraoxonase and arylesterase activity of PON1 significantly (p < 0.001) increased after the intervention. There were however no significant changes in serum triglyceride and HDL-C. There was a significant positive correlation between paraoxonase and arylesterase activity of PON1 and serum HDL-C concentration A significant negative correlation was detected between paraoxonase and arylesterase activity of PON1 and FBS.Conclusion: It can be concluded that PJ consumption as an antioxidant may have a contribution in changing fasting blood sugar, lipid profiles, lipoprotein oxidation, and PON1 activity. © 2012 parsaeyan et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 20 条
[1]  
Aldridge W.N., Serum esterase II: an enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera, Biochem J, 53, pp. 117-124, (1953)
[2]  
La Du B.N., Human serum paraoxonase/arylesterase, Pharmacogenetics of Drug Metabolism, pp. 51-91, (1992)
[3]  
Gordon D., Where should the clinician stand?, HDL, pp. 17-20, (1992)
[4]  
Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N., Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus, Atherosclerosis, 86, pp. 193-198, (1991)
[5]  
Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N., Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitusand its relationship to serum lipids and lipoproteins, Arterioscler Thromb Vasc Biol, 15, pp. 1812-1818, (1995)
[6]  
Ikeda Y., Suehiro T., Inoue M., Nakauchi Y., Morita T., Arii K., Ito H., Kumon Y., Hashimoto K., Serum paraoxonase activity and its relationship to diabetic complications in patients with noninsulin-dependent diabetes mellitus, Metabolism, 47, pp. 598-602, (1998)
[7]  
Inoue M., Suehiro T., Nakamura T., Ikeda Y., Kumon Y., Hashimoto K., Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes, Metabolism, 49, pp. 1400-1405, (2000)
[8]  
Mackness M.I., Arrol S., Mackness B., Durrington P.N., The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation, Lancet, 349, pp. 851-852, (1997)
[9]  
Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N., Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification, FEBS Lett, 423, pp. 57-60, (1998)
[10]  
Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., La Du B.N., Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective active of human paraoxonase alloenzymes Q and R, Arterioscler Thromb Vasc Biol, 10, pp. 1617-1624, (1998)
12